Vincerx Pharma Files 8-K on Exit Costs and Other Events
Ticker: VINC · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | 8-K |
| Filed Date | Dec 6, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $0.3 million, $0.6 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, financial-reporting
Related Tickers: VINC
TL;DR
Vincerx Pharma (VINC) filed an 8-K detailing exit/disposal costs and other events.
AI Summary
Vincerx Pharma, Inc. filed an 8-K on December 6, 2024, reporting on cost associated with exit or disposal activities and other events. The filing also includes financial statements and exhibits. The company was formerly known as LifeSci Acquisition Corp. and Vincera Pharma, Inc.
Why It Matters
This filing indicates potential restructuring or divestiture activities within Vincerx Pharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Filings related to exit or disposal activities can signal significant business changes or financial distress, warranting closer investor scrutiny.
Key Numbers
- 001-39244 — SEC File Number (Identifies the company's filing history)
- 83-3197402 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Vincerx Pharma, Inc. (company) — Registrant
- LifeSci Acquisition Corp. (company) — Former company name
- Vincera Pharma, Inc. (company) — Former company name
- 0001796129 (company) — Central Index Key
- 20241206 (date) — Filing date
- 20241202 (date) — Earliest event reported date
FAQ
What specific activities are associated with the 'Cost Associated with Exit or Disposal Activities'?
The filing does not provide specific details on the nature of the exit or disposal activities, only that costs are associated with them.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing was on December 2, 2024.
What were Vincerx Pharma's former company names?
Vincerx Pharma, Inc. was formerly known as Vincera Pharma, Inc. and LifeSci Acquisition Corp.
What is Vincerx Pharma's principal executive office address?
The principal executive offices are located at 260 Sheridan Avenue, Suite 400, Palo Alto, California 94306.
What is the SIC code for Vincerx Pharma, Inc.?
The Standard Industrial Classification code for Vincerx Pharma, Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 1,108 words · 4 min read · ~4 pages · Grade level 13.4 · Accepted 2024-12-06 16:04:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VINC The Nasdaq
- $0.3 million — ny estimates that it will incur between $0.3 million and $0.6 million in costs primarily rel
- $0.6 million — it will incur between $0.3 million and $0.6 million in costs primarily related to severance
Filing Documents
- d829648d8k.htm (8-K) — 30KB
- d829648dex991.htm (EX-99.1) — 13KB
- g829648g1205081104035.jpg (GRAPHIC) — 6KB
- 0001193125-24-272442.txt ( ) — 182KB
- vinc-20241202.xsd (EX-101.SCH) — 3KB
- vinc-20241202_lab.xml (EX-101.LAB) — 18KB
- vinc-20241202_pre.xml (EX-101.PRE) — 11KB
- d829648d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated December 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 6, 2024 VINCERX PHARMA, INC. By: /s/ Alexander A. Seelenberger Name: Alexander A. Seelenberger Title: Chief Financial Officer